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Abl family tyrosine kinases govern IgG
extravasation in the skin in a murine
pemphigus model
Sachiko Ono1, Gyohei Egawa1, Takashi Nomura1, Akihiko Kitoh1, Teruki Dainichi 1, Atsushi Otsuka1,
Saeko Nakajima1, Masayuki Amagai2, Fumi Matsumoto3, Mami Yamamoto 3, Yoshiaki Kubota4,
Toshiyuki Takai5, Tetsuya Honda1 & Kenji Kabashima 1,6
The pathway of homeostatic IgG extravasation is not fully understood, in spite of its
importance for the maintenance of host immunity, the management of autoantibody-
mediated disorders, and the use of antibody-based biologics. Here we show in a murine
model of pemphigus, a prototypic cutaneous autoantibody-mediated disorder, that blood-
circulating IgG extravasates into the skin in a time- and dose-dependent manner under
homeostatic conditions. This IgG extravasation is unaffected by depletion of Fcγ receptors,
but is largely attenuated by specific ablation of dynamin-dependent endocytic vesicle for-
mation in blood endothelial cells (BECs). Among dynamin-dependent endocytic vesicles, IgG
co-localizes well with caveolae in cultured BECs. An Abl family tyrosine kinase inhibitor
imatinib, which reduces caveolae-mediated endocytosis, impairs IgG extravasation in the skin
and attenuates the murine pemphigus manifestations. Our study highlights the kinetics of IgG
extravasation in vivo, which might be a clue to understand the pathological mechanism of
autoantibody-mediated autoimmune disorders.
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Immunoglobulins (Igs), including autoantibodies, are initiallyproduced in the lymphoid organs and circulate throughout thebody via the blood. Considering the increased risk of cuta-
neous bacterial infections in patients with primary agammaglo-
bulinemia1, extravasation of Igs should exert essential protective
immune functions especially in the skin. In addition, extravasa-
tion of Igs in the skin might also be related to the establishment of
pathogenic immune reactions, such as cutaneous urticaria
mediated by IgEs or the occurrence of autoimmune skin blis-
tering disorders by autoantibodies against epidermal adhesion
molecules2–4.
It was reported that blood-circulating IgE can bind to the high-
affinity Fcε receptors of dermal perivascular mast cells, which
elongate their dendrites through the blood vessel wall5. As for
IgG, although we recently showed that local inflammation
enhances its extravasation6, the mechanisms of homeostatic IgG
extravasation was left unaddressed. Understanding the molecular
mechanism of this process is essential for the management of
autoantibody-mediated disorders. Moreover, considering that
antibody-based biologics or immune checkpoint inhibitors are
globally accepted as strong tools for the treatment of autoimmune
disorders and various cancers, this insight into the basic per-
ipheral kinetics of IgG would serve as practical information in the
clinic.
Generally, there are two pathways of transvascular transport
for plasma contents: paracellular (passive transport) and trans-
cellular (active transport)6. Most blood vessels in peripheral tis-
sues including the skin are composed of continuous blood vessels,
and serve as a firm physiological barrier against plasma contents.
Since the barrier prevents paracellular diffusion of albumin
(Molecular size= 66 kilodalton [kDa]) and dextran with a
molecular size of over 70 kDa7–9, it seems unlikely that IgG
(150 kDa) takes the paracellular pathway under homeostatic
conditions. Nevertheless, a variety of plasma macromolecules
takes the transcellular pathway by means of receptors expressed
in vesicles of blood endothelial cells (BECs), which are derived
from various forms of endocytosis10–13. Previous observations
revealed the close localization of IgG and Fcγ receptors in vesi-
cles, such as neonatal Fc receptor (FcRn) or FcγRIIb14–18. In
addition, FcRn-unbound IgG is shown to enter into lysosomal
degradation in BECs19–23. Although these studies implicate the
importance of FcRn, Fcγ receptors, and endocytic vesicles for
subcellular trafficking of IgG, their actual contribution to IgG
extravasation in vivo remains to be addressed.
In relation to the transvascular transport, it was reported that
a multityrosine kinase inhibitor, imatinib, relieved tissue edema
upon inflammation in murine models of acute lung injury and
cerebral infarction24–27. Another study also pointed out that
imatinib relieves IgE-mediated anaphylactic reaction in mice28.
The efficacy of imatinib in these models is mainly attributed to
the decreased paracellular permeability via inhibition of the
Abl family of tyrosine kinases25,26,28. In addition, imatinib
and another Abl inhibitor was shown to downregulate
caveolae-mediated endocytosis in vitro in BECs29,30. We thus
hypothesized that imatinib may also modulate IgG extravasa-
tion in the skin under both inflammatory and homeostatic
conditions.
Pemphigus vulgaris is a prototypic antibody-mediated disorder
that targets a keratinocyte adhesion molecule, desmoglein (Dsg)
3, among other targets. Herein, using a murine model of pem-
phigus by targeting Dsg3, we examined how extravasation of
blood-circulating IgG is regulated under homeostatic conditions.
With the passive murine model used in this study, we did not
address initiation of autoantibody response or the target specifi-
city, but simply focused on the kinetics of IgG extravasation
in vivo. In addition, we evaluated the relevance of Fcγ receptors
and the effect of imatinib and other Abl inhibitors on IgG
extravasation in the skin.
Results
Blood-circulating IgG extravasates and reaches the epidermis.
We employed a passive murine pemphigus model that can be
induced by intravenous injection of antimurine Dsg3 antibodies
(Abs) to mice31. Among various antimurine Dsg3 Ab clones, a
pathogenic clone (AK23) disrupts cell–cell adhesion between
keratinocytes and induces hair loss in mice, but a nonpathogenic
clone (AK18) does not31 (Fig. 1a). Because the dissociation of
keratinocytes may evoke local inflammation that may hinder the
subsequent analysis, we used AK18 to evaluate the kinetics of IgG
extravasation in a sensitive and quantitative way.
AK18, which belongs to the IgG1 subtype, was injected
intravenously from the tail vein to mice. Twenty-four hours later,
the deposition of AK18 in the ear epidermis was quantified by
measuring the mean fluorescence intensity (MFI) of IgG1 in the
CD45−E-cadherin+ keratinocytes by flow cytometry (hereafter
referred to as IgG1-MFI) (Fig. 1b). IgG1-MFI started to elevate
within 1 h and reached a plateau at 6 h after the intravenous
injection (Fig. 1c). The injection doses of AK18 were associated
with dose-dependent increases in IgG1-MFI (r= 0.99; evaluated
24 h after the AK18 injection) (Fig. 1d). To reflect high IgG1-
MFI, AK18 deposition in the epidermis was detectable
by immunohistochemistry when mice received a high dose
(>100 μg) of Ab as we previously reported6 (Fig. 1e). With
injection of AK23, the manifestation of hair loss and epidermal
AK23 deposition in host mice were detected only under a high-
injection dosage (Fig. 1a, e). These results emphasize similar
kinetics of AK18 and AK23, and support the idea that the amount
of autoantibody deposition is critical for the establishment of the
pemphigus skin manifestation. In order to check whether
nonspecific IgG, not restricted to anti-Dsg3 Abs, extravasates
from the blood to the dermal interstitium under homeostatic
conditions, we intravenously injected fluorescein-conjugated
nonspecific mouse IgG to mice. Twenty-four hours later, by the
whole mount immunohistochemistry of the split ear skin, we
found that dermal macrophages were labeled, suggesting that they
received extravasated IgG in the dermis (Fig. 1f, g).
These results confirmed that the blood-circulating IgG,
including autoantibodies, crosses over the blood vessel walls
and distributes in the skin in a time- and circulating Ab dose-
dependent manner under homeostatic conditions.
Homeostatic IgG extravasation occurs transcellularily via
BECs. To determine whether IgG extravasation takes place via
the transcellular pathway or the paracellular pathway under
homeostatic conditions, we examined IgG kinetics by intravital-
imaging analysis of murine ears. We intravenously injected
fluorescein-conjugated IgG and found that injected IgG retained
in the blood circulation. The leakage of IgG to the dermal
interstitium was not apparent for an hour (Fig. 2a). Besides, the
leakage of IgG was clearly demonstrated when local inflammation
was induced by topical phorbol myristate acetate (PMA) to the
ears (Fig. 2a and Supplementary Fig. 1A). On the other hand,
internalization of AK18 in dermal BECs was detected by intra-
cellular staining of IgG1 in the dermal BECs after an intravenous
Ab injection (Fig. 2b, c). Therefore, the transcellular pathway is
likely the main route for homeostatic IgG extravasation in the
skin.
In the transcellular pathway, three major conventional ways are
known for the formation of endocytic vesicles: caveolae-mediated
endocytosis, clathrin-mediated endocytosis, and macropinocyto-
sis10. Among them, dynamin governs endocytic membrane
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fission and formation of caveolae-mediated and clathrin-
mediated endocytic vesicles. To evaluate the role of dynamin-
dependent vesicles in BECs for IgG extravasation, we mated VE-
cadherin-CreERT2 transgenic mice with dynamin 1 and 2 double
conditional knockout mice (VE-cadherin-CreERT2; D1D2-floxed
mice)32,33. In these mice, the formation of both clathrin-mediated
and caveolae-mediated endocytic vesicles was ablated selectively
in BECs after the intraperitoneal injections of tamoxifen. We
confirmed by electron microscopy that vesicles in dermal BECs
were diminished in Cre+ mice after tamoxifen treatment
compared with Cre− control mice (Fig. 2d, red arrowheads).
The interendothelial adhesion junction was unaffected in Cre+
mice as well as Cre− control mice under homeostatic condition
(Fig. 2d, yellow arrows). In such condition, both epidermal AK18
deposition (evaluated by IgG1-MFI) and internalization of AK18
in dermal BECs were reduced (Fig. 2e, f). Consistently, the
enhancement of dermal macrophages after intravenous injection
of fluorescein-conjugated IgG was also attenuated in Cre+ mice,
and IgG retained in the blood circulation (Supplementary
Fig. 1B). These observations indicate that the transcellular
pathway is responsible for homeostatic IgG extravasation to the
skin, and that dynamin-dependent endocytic vesicles in BECs are
favorable cargo beds.
On the other hand, upon inflammation with topical PMA
application to the ears, the ear swelling levels was unaffected









































































































Fig. 1 Kinetics of homeostatic IgG extravasation in the skin. aManifestation of hair loss in mice 10 days after intravenous injection of AK18 or AK23 at 10 or
100 μg. b A representative flow cytometry plot and a histogram (the left and middle panels) to detect epidermal AK18 deposition in CD45+ E-cadherin+
keratinocytes, and IgG1-MFI (the right panel) in keratinocytes 24 h after intravenous injection of 20 μg AK18 (n= 4), 20 μg control mouse IgG1 (Ctrl-
mIgG1) (n= 4), or PBS (n= 3). *P < 0.05 (a one-way ANOVA test). NS not significant. c A plot of epidermal IgG1-MFI against time after 100 μg of AK18
injection (n= 2 for each time point). d A plot of AK18 injection dose against epidermal ΔIgG1-MFI (the changes in IgG1-MFI from PBS-injected sample) 24
h after AK18 injection (n= 2 for each injection dose, two-tailed Spearman rank-correlation test). e Immunohistochemical evaluation in the mouse ear 24 h
after intravenous injection of AK18 or AK23 at 10 or 100 μg, PBS, and 100 μg of control mouse IgG1 (Ctrl-mIgG1). Yellow arrows represent deposition of
mouse IgG (mIgG) in keratinocytes. Blue represents nuclei stained with DAPI. White dotted line represents the border between the epidermis or the hair
bulb and the dermis. Scale bar= 20 μm. f Images of ear skin dermis 24 h after intravenous injection of A555-conjugated mIgG or PBS. Scale bar= 100 μm.
g The percentage of dermal macrophages positive for the fluorescein evaluated by flow cytometry, 24 h after intravenous injection of A647-conjugated
mIgG (n= 6) or PBS (n= 4). *P < 0.05 (t-test). In each figure, the error bars represent the standard deviation of a data set
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comparable between Cre+ and Cre− control mice (Supplemen-
tary Fig. 1C), after the intravenous injection of fluorescein-
conjugated IgG. In addition, epidermal AK18 deposition of Cre+
mice was also comparable with that of control mice in inflamed
ears (Fig. 2h). These results suggest that the robust increase in the
paracellular permeability upon inflammation is unaffected in VE-
cadherin-CreERT2; D1D2-floxed mice, and that the defect of
transcellular IgG extravasation is negligible in such situations.
Together with our previous report showing that epidermal IgG
deposition was markedly increased in inflamed ears compared
with untreated ears6, we concluded that the transcellular IgG-
extravasation pathway is less important under inflammatory
conditions when paracellular leakage is dominant.
Caveolae mediates IgG extravasation in the skin. We attempted
to clarify which vesicles are responsible for homeostatic IgG
extravasation. We cultured human dermal BECs (HDBECs) with
fluorescein-conjugated human IgG and observed subcellular IgG
distribution in HDBECs, which might be derived from active
endocytosis. IgG in HDBECs colocalized with EEA1, a marker of
early endosomes, in foci within the cytoplasm (stained with
CellMask Green), while being resistant to the acid wash by acetic
acid34, suggesting that IgG was internalized in HDBECs (Fig. 3a
and Supplementary Fig. 2). We found that this IgG endocytosis
by HDBECs was decreased when cultured with dynasore, an
inhibitor of dynamin (Fig. 3b). The result was consistent with the
observations in VE-cadherin-CreERT2; D1D2-floxed mice
(Fig. 2e, f). To compare the dominance of clathrin- or caveolae-
mediated endocytosis in IgG uptake, we conducted an immu-
nocytochemical analysis. IgG taken up by HDBECs was
circumscribed by or colocalized with caveolin 1, the principal
protein of caveolae, rather than with clathrin (Fig. 3c). In addi-
tion, IgG endocytosis was suppressed in HDBECs with a
caveolae-conformation inhibitor, nystatin35 (Fig. 3d), or siRNA
against caveolin 1 but not siRNA against clathrin (Fig. 3e and
Supplementary Fig. 3).
To study the effect of nystatin in vivo, we injected nystatin
intraperitoneally before the intravenous AK18 administration,
and evaluated epidermal IgG1-MFI. Correspondingly, we found
that nystatin pretreatment significantly reduced epidermal AK18
deposition in mice (Fig. 3f). These results suggest the dominant
contribution of caveolae-mediated endocytosis in IgG
extravasation.
Fcγ receptors play negligible roles in IgG extravasation. As
mentioned, many plasma macromolecules use their receptors
expressed on the membrane of endocytic vesicles in the trans-
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Fig. 2 Homeostatic IgG extravasation in the skin relies on the transcellular pathway and dynamin-dependent endocytic vesicles in BECs. a Time-lapse
images of paracellular IgG leakage (15 min after intravenous injection of fluorescein-conjugated IgG via the tail vein) in the ear dermis (the upper panels)
exhibited in the rainbow color scale. Scale bar= 150 μm. Kinetics of MFI in the blood vessel area (red) and in the interstitium area (blue) in the dermis are
plotted in the lower panels. b Representative flow cytometry plots for the identification of injected AK18 (dotted-line box) in dermal BECs of the mouse ear
by flow cytometry. c The % frequency of IgG1-positive BECs 24 h after intravenous AK18 injection (n= 7) or PBS (n= 5), compared with isotype-stained
control. *P < 0.05 (t-test). d Electron microscopic images of dermal BECs in the ear skin evaluated in VE-cadherin-CreERT2; D1D2-floxed mice in
homeostatic condition. Red arrowheads show intracellular vesicles. Yellow arrows show interendothelial junctions. Scale bar= 500 nm. e, f Epidermal
IgG1-MFI (e) and the % frequency of IgG1-positive BECs (f) 24 h after 100 μg of intravenous AK18 injection or PBS in VE-cadherin-CreERT2; D1D2-floxed
mice (n= 5 for Cre− or n= 4 for Cre+, both ears were evaluated separately in e). *P < 0.05 (t-test). g, h The ear thickness changes (g) and epidermal
IgG1-MFI (h), 24 h after 20 μg of intravenous AK18 injection or PBS and topical PMA application to the ears, in VE-cadherin-CreERT2; D1D2-floxed mice (n
= 6 for Cre− and n= 5 for Cre+). In each figure, the error bars represent the standard deviation of a data set
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skin also depends on any of Fcγ receptors, especially FcγRIIb, or
FcRn, we examined the expression of Fcγ receptors or FcRn on/in
murine dermal BECs. Similar to the previous observations of
placental BECs14,18, dermal BECs expressed low levels of FcγRIIb
and/or FcγRIII and high levels of FcRn, but did not express FcγRI
or FcγRIV (Fig. 4a).
To evaluate the role of FcγRIIb or FcγRIII for IgG extravasation
in an in vivo setting, epidermal AK18 deposition was examined
after intravenous Ab injection in FcγRIIb-deficient mice36 and
FcRg-deficient mice that lack the expression of Fcγ receptors other
than FcγRIIb37. In both mouse strains, IgG1-MFI was found to be
comparable with that of wild-type mice (Fig. 4b, c).
As for FcRn, we further employed β2-microglobulin (β2m)-
deficient mice that lack functional FcRn38. The reliability of FcRn
deficiency was first determined by evaluating transplacental AK18
transport to the fetal epidermis39. In brief, the β2m-hemi-
deficient female mouse was mated with the β2m-hemi-deficient
male mouse. Twenty-four hours after the intravenous adminis-
tration of AK18 to the pregnant female mouse at gestational day
18.5, fetuses were delivered by cesarean section, and AK18
deposition in the fetal epidermis was analyzed by flow cytometry.
Each fetal genotype was also examined. Supportively, AK18
deposition in the skin was completely blocked in β2m-deficient
fetuses and half-reduced in β2m-hemi-deficient fetuses compared
with wild-type littermates (Fig. 4d). In contrast, in adult mice,
epidermal AK18 deposition and serum AK18 levels in β2m-
deficient mice were comparable with those in control mice 6 h
after AK18 injection (Fig. 4e). These results suggest that FcRn is
not essential for homeostatic IgG extravasation in the skin. Of
note, epidermal AK18 deposition was decreased at a later time
point (24 h after injection) in β2m-deficient mice (Fig. 4f, left),
likely reflecting decreased serum AK18 levels caused by impaired
IgG-recycling in BECs (Fig. 4f, right).
In addition, we applied intravenous immunoglobulin (IVIG)
treatment as an alternative way to block FcRn function.
Consistent with the previous report39, IVIG at the dosage of
1.0 g kg−1 day−1 could completely prevent the transplacental
AK18 transfer to fetuses (Fig. 4g). In this condition, however,
epidermal AK18 deposition in the adult mice was not prevented:
epidermal AK18 deposition and the serum AK18 levels were
comparable with that of control mice at 6 h after AK18
administration (Fig. 4h), and both were partially decreased at
24 h after AK18 administration (Fig. 4i). These results were
compatible with the results of β2m-deficient mice (Fig. 4d–f), and
also supported our idea that FcRn is unessential for transvascular
IgG transport in the skin.
Considering these observations, we concluded that the
extravasation of IgG in the skin is mediated without the support
of Fcγ receptors, including FcγRIIb or FcRn.
Imatinib reduces IgG extravasation in the skin. We next
examined whether a multityrosine kinase inhibitor, imatinib,





































































































































Fig. 3 Caveolae mediate IgG endocytosis in BECs. a Subcellular human IgG (hIgG) distribution in BECs (magenda) co-stained with anti-EEA1 Ab (cyan).
Blue represents a nucleus stained with DAPI. Scale bar= 10 μm. b hIgG distribution in dynasore- or vehicle (DMSO)-treated BECs. Scale bar= 20 μm.
ΔA594-MFI of cells of each group is plotted in the right panel (n= 10 and 12 cells, each). *P < 0.05 (t-test). c Immunohistochemistry of caveolin 1 (CAV1)
or clathrin (CLTC) (cyan) and hIgG (magenda) in BECs (the left panels). Yellow arrowheads represent the merging dots of green and red. Scale bar= 10
μm. The right panel shows the number of merging dots in each cell (n= 10 cells, each). *P < 0.05 (t-test). d, e The left panels show hIgG distribution in
nystatin- or vehicle-treated BECs (d), and BECs treated with siRNA that targets caveolin 1 (CAV1), clathrin (CLTC), or nontargeting siRNA (e). Scale bar=
20 μm. The right panel shows ΔA594-MFI of BECs treated with nystatin or vehicle (DMSO) (d, n= 9 and 10 cells, each), and BECs treated with siRNA
that targets caveolin 1 (CAV1), clathrin (CLTC), or nontargeting siRNA (e, n= 22, 23, and 25 cells, respectively) after the IgG endocytosis assay. *P < 0.05
(d t-test and e a one-way ANOVA test). f IgG1-MFI of ear epidermis 6 h after PBS (n= 4) or 100 μg of AK18 injection, pretreated with nystatin or vehicle
(Veh) (n= 4, both ears were evaluated separately in each group). *P < 0.05 (t-test). In each figure, the error bars represent the standard deviation of a
data set
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reports showing a unique effect of imatinib on regulating vascular
permeability24,26,27. These reports demonstrated the impact of
imatinib under inflammatory conditions. As such, we first eval-
uated whether imatinib could reduce IgG extravasation in
inflammation.
As we previously reported, the local skin inflammation induced
by various stimuli including topical PMA significantly enhances
autoantibody deposition in the epidermis in our murine
pemphigus model6. We administered imatinib intraperitoneally
to mice before the intravenous AK18 injection and found that
imatinib reduced epidermal AK18 deposition in the inflamed ears
(Fig. 5a). Therefore, we assumed that imatinib regulated, at least
in part, the paracellular permeability of IgG in our model. This
observation is consistent with previous reports exhibiting the
impact of imatinib on vascular permeability under inflammatory
conditions. The PMA-induced ear swellings were unaffected by
imatinib (Fig. 5b), probably due to the fact that the amount of ear
swelling is determined not only by vascular permeability.
Next, we examined the influence of imatinib on IgG
extravasation under homeostatic conditions. We treated mice
with imatinib or vehicle (distilled water: dH2O) before the AK18
administration, and found that epidermal AK18 deposition was
suppressed in a dose-dependent manner by imatinib (Fig. 5c). A
high-dose imatinib pretreatment (6000 μg body−1 day−1) almost
completely blocked Ab deposition, even when AK18 was injected
at a high dose (up to 200 μg body−1) (Fig. 5d). Serum AK18 levels
were comparable between imatinib- and vehicle-pretreated mice
(Fig. 5e), while internalization of AK18 in dermal BECs was
largely decreased (Fig. 5f), similar to the results in VE-cadherin-
CreERT2; D1D2-floxed mice (Fig. 2d, e). These results suggest
that Ab extravasation is blocked at the phase of IgG endocytosis
in BECs by imatinib.
We additionally tested if imatinib could also block extravasa-
tion of nonspecific IgG. Pretreatment of imatinib prevented the
internalization of IgG by dermal macrophages after an intrave-
nous injection of fluorescein-conjugated mouse IgG (Fig. 5g).
This result suggests that IgG is constrained to the blood
circulation by treatment with imatinib. Because this decrease in
IgG uptake by dermal macrophages was recovered by an
























































































































































































































Fig. 4 Dispensable contribution of Fcγ receptors for homeostatic IgG extravasation in the skin. a Expression of each Fcγ receptor on BECs in the ear skin (solid
line). Fill drawing represents isotype-stained control. b, c IgG-MFI of ear epidermis 24 h after intravenous AK18 injection in FcγRIIb-deficient (FcγRIIb−/−)
mice (b) and FcRg-deficient (FcRg −/−) mice (c), compared with wild-type (WT) mice (n= 7, each in b and n= 6, each in c). d IgG1-MFI of dorsal epidermis
of neonates (WT [β2m+/+], β2m-hemi-deficient [β2m+/-], or β2m-deficient [β2m−/−]) delivered from β2m+/− parents (n= 2, 5, or 4 for each littermate),
24 h after intravenous administration of AK18 or PBS (n= 5) to the mothers. e IgG1-MFI of ear epidermis (the left panel) or serum AK18 levels (the right
panel) in WT or β2m−/− adult mice 6 h after intravenous AK18 injection (n= 3, each. Both ears were evaluated separately for IgG1-MFI). f IgG1-MFI of ear
epidermis (the left panel) or serum AK18 levels (the right panel) in WT or β2m−/− adult mice 24 h after AK18 injection (n= 3, each. Both ears were evaluated
separately for IgG1-MFI). *P < 0.05. g IgG1-MFI of fetuses from pregnant mice after intravenous AK18 injection, pretreated with 1.0 g kg−1 day−1 of IVIG or PBS
(n= 7 or 6, each). PBS-injected mothers were used as the control (n= 4). h IgG1-MFI of ear epidermis (the left panel, n= 4, each. Both ears were evaluated
separately) or serum AK18 levels (the right panel, n= 3) in adult mice 6 h after intravenous AK18 injection, treated with IVIG at 1.0 g kg−1 day−1 or PBS. i IgG1-
MFI of ear epidermis (the left panel, n= 4, each) or serum AK18 levels (the right panel, n= 3, each) in adult mice 24 h after intravenous AK18 injection,
treated with IVIG at 1.0 g kg−1 day−1 or PBS. A parametric Student’s t-test was applied to each experiment. In each figure, the error bars represent the standard
deviation of a data set
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functions by inducing the dysfunction of phagocytic activity of
macrophages. Flow cytometric analysis yielded similar results,
showing that the imatinib pretreatment reduced the percentage of
fluorescein-positive dermal macrophages after an intravenous
injection of fluorescein-conjugated mouse IgG, but not after an
intradermal injection (Fig. 5h).
These results suggest that imatinib blocks IgG extravasation to
the skin not only upon inflammation but also under homeostatic
conditions by interfering in both paracellular leakage of IgG as
well as endocytosis of IgG in BECs.
Abl family tyrosine kinases in BECs govern IgG extravasation.
Imatinib is known to target the Abl family of nonreceptor tyr-
osine kinases (c-Abl and Arg) and some membrane-bound tyr-
osine kinase receptors such as platelet-derived growth factor
receptor (Pdgfr)-α, Pdgfr-β, and c-Kit40. As mentioned, the effi-
cacy of imatinib on vascular permeability seems to be mainly
attributed to the inhibition of Abl family tyrosine kinases25,26,28.
Of note, a previous report proposed the effect of imatinib on
regulating vascular permeability during ischemic stroke through
its action on Pdgfr-α on pericytes27. This raises the possibility
that tyrosine kinases other than those of the Abl family may also
play a role in IgG extravasation.
To define the importance of Abl family tyrosine kinases on IgG
extravasation, we examined the contribution of other membrane-
bound tyrosine kinases (Pdgfr-α, Pdgfr-β, and c-Kit) on BECs.
We analyzed the expression of these tyrosine kinase receptors on
murine dermal BECs by flow cytometric analysis, and found
expression of Pdgfr-α, but not Pdgfr-β or c-Kit (Supplementary
Fig. 4A). We then pretreated mice with a sufficient dose of an
anti-Pdgfr-α blocking Ab, APA541, before the AK18 administra-
tion, however, epidermal AK18 deposition was not affected
(Supplementary Fig. 4B).
We also examined the possible contribution of mast cells, since
imatinib affects their functions by inhibiting c-Kit activity42.
Dermal mast cells locate along blood vessels and were shown to
have a potency to capture blood-circulating IgE via Fcε
receptors5. Because mast cells also possess Fcγ receptors (FcγRIIb
and/or FcγRIII but not FcγRI nor FcγRIV) (Supplementary
Fig. 4C), we assumed that they might even be engaged in
transferring IgG to tissue interstitium. Moreover, even under
homeostatic conditions, subtle physiological stimuli may activate
mast cells to induce histamine release and increase blood vessel
permeability6. To reveal the role of mast cells in homeostatic IgG
extravasation, we employed inducible mast cell-deficient (Mas-

















































































































































Fig. 5 Imatinib reduces IgG extravasation in the skin. a IgG1-MFI of ear epidermis 24 h after 5–20 μg of AK18 injection and topical PMA to the ears,
pretreated with imatinib (6000 μg body−1) or vehicle (n= 4, respectively). *P < 0.05 (t-test). b The ear thickness changes 24 h after topical PMA to the
ears pretreated imatinib (6000 μg body−1) or vehicle (n= 6, each. Both ears were evaluated separately). c IgG1-MFI of ear epidermis 24 h after 100 μg of
AK18 injection, pretreated with imatinib (0–6000 μg body−1) or vehicle (n= 4, respectively). d IgG1-MFI of ear epidermis 24 h after 50–200 μg of AK18
injection pretreated with imatinib (6000 μg body−1) (n= 3 or 4, respectively). *P < 0.05 (t-test). e Serum AK18 levels 24 h after 100 μg of AK18 injection
pretreated with imatinib (6000 μg body−1) or vehicle (n= 3, each). f The left panel shows IgG1-positive cells in BECs 24 h after 100 μg of AK18 injection
with imatinib (6000 μg body−1) or vehicle pretreatment. The right panel shows % frequency of IgG1-positive cells in BECs (n= 6). *P < 0.05 (t-test).
g, h The whole mount image of the ear dermis (g) and the percentage of dermal macrophages evaluated by flow cytometry (h), positive for fluorescein
after intravenous (i.v.) or intradermal (i.d.) fluorescein-conjugated mIgG injection, with imatinib (6000 μg body−1) or vehicle pretreatment (n= 6 or 5 for
i.v. and n= 6 for i.d., respectively). Scale bar= 100 μm *P < 0.05 (t-test). In each figure, the error bars represent the standard deviation of a data set
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Fig. 4D), IgG1-MFI was comparable with that in mast cell
sufficient controls (Supplementary Fig. 4E).
To further investigate the direct effect of Abl family tyrosine
kinases on IgG extravasation, we examined IgG endocytosis by
HDBECs that were exposed to siRNA against c-ABL. We
confirmed that IgG endocytosis by HDBECs was decreased when
cultured with siRNA against c-ABL, as well as siRNA against
caveolin 1 (Fig. 6a). In addition, we conducted an in vitro
transwell permeability assay using human dermal microvascular
endothelial cells (HDMECs). As expected, imatinib showed an
inhibitory effect on thrombin-induced IgG transition through
HDMECs in a dose-dependent manner (Fig. 6b). Similarly,
asciminib, another specific inhibitor of c-Abl tyrosine kinase43,
also showed reduced IgG transition through HDMECs (Fig. 6c).
Inhibition of both Abl and Arg with GNF-2, which displays a
greater target specificity than imatinib and is not known to inhibit
any additional kinases44,45, almost completely abolished IgG
transition through HDMECs at concentrations >1 μM (Fig. 6d).
These results indicate that Abl family tyrosine kinases, including
both c-Abl and Arg, are essential for IgG transport through BECs.
We additionally evaluated the in vivo effect of reagents that
have a specific effect on Abl family tyrosine kinases other than
imatinib. We examined 5-aminoimidazole-4-carboxamide ribo-
nucleotide (AICAR)30, which was newly identified to inhibit Abl
phosphorylation by activating adenosine monophosphate-
dependent kinase. Although increasing number of studies
assessed the antimetabolic and immunomodulatory effect of
AICAR and its analog in vivo46–48, its effect on IgG kinetics
remains unknown. Pretreatment with AICAR was effective in
reducing epidermal AK18 deposition (Fig. 6e). These results
support that Abl family tyrosine kinases in BECs play an essential
role in homeostatic IgG extravasation in the skin.
Imatinib reduces extravasation of IgG but not of dextran. To
examine if the effect of imatinib is specific on caveolae and
extravasation of IgG, mice were intravenously injected with
Alexa-Fluor 594 (A594)-conjugated mouse IgG together with
fluorescein isothiocyanate (FITC)-conjugated 150 kDa dextran
(a similar molecular weight with IgG), which is generally con-
sidered to be taken up by macropinocytosis and/or noncaveolae
and clathrin-independent endocytosis49–52. Extravasation of both
molecules was depicted as enhancement of dermal macrophages
that engulfed these macromolecules (Supplementary Fig. 5A).
While imatinib reduced extravasation of IgG, it did not reduce
the extravasation of 150 kDa dextran (Supplementary Fig. 5A).
Likewise, flow cytometric analysis demonstrated that the per-
centage of dermal macrophages that engulfed FITC-conjugated
dextran was not decreased by the imatinib pretreatment (Sup-
plementary Fig. 5B). These results indicate the different extra-
vasation routes of IgG and dextran, and suggest a selective effect
of imatinib on caveolae-mediated endocytosis in BECs.
Imatinib prevents the hair loss in a murine pemphigus model.
We tested the possibility of regulating IgG extravasation as a
therapeutic target for autoantibody-mediated disorders. Mice
were treated with imatinib before the administration of a
pathogenic autoantibody, AK23. Imatinib attenuated the devel-
opment of severe hair loss in mice (Fig. 7a) by preventing hair
acantholysis (the disruption of cell–cell adhesion between kera-
tinocytes in the hair follicles) (Fig. 7b). AK23 deposition in
interfollicular and follicular keratinocytes was ablated for 5 days
after imatinib treatment (Fig. 7c). Similar to the observation for
AK18 (Fig. 5e), serum AK23 levels were comparable between
imatinib- and vehicle-treated mice until the elimination of
injected AK23 from the blood (Fig. 7d), suggesting that imatinib
had a marginal effect on degradation or recycling of auto-
antibodies. In contrast to intravenous injection, hair loss (Fig. 7e)
and AK23 deposition in interfollicular and follicular keratinocytes
(Fig. 7f) was not abrogated by imatinib after the intradermal
injection of AK23. This supports the idea that imatinib is likely to
elicit its action via blocking Ab extravasation rather than inter-
fering with Ab deposition to the epidermis or attenuation of its
pathogenic activity. These observations suggest that imatinib has
a potential to prevent the development of murine pemphigus skin
manifestations.
We additionally tested if imatinib could also block extravasa-
tion of autoantibodies in mice obtained from pemphigus patients,
capitalizing on the ability of pemphigus autoantibodies in
humans to react with murine Dsgs6. Mice were intravenously
injected with sera obtained from two pemphigus patients, who are
positive for anti-Dsg3 Abs composed of IgG1 and
IgG4 subclasses. By immunohistochemical analysis, we detected
both human IgG1 and IgG4 deposition in the epidermis when
mice were injected with 100 μl of each patient’s serum, whereas it
became undetectable with imatinib pretreatment (Supplementary
Fig. 6). Taken together, these findings allowed us to consider that
imatinib reduces the autoantibody deposition in the skin and
protects from the autoantibody-mediated pathological changes.
Discussion
Our findings highlight a distinct pathway for homeostatic IgG
extravasation in vivo and the impact of Abl family tyrosine
kinases on IgG kinetics at the blood–tissue interface. Homeostatic
IgG transport from the blood to the skin interstitium occurs via
the transcellular pathway through dermal BECs, which uses IgG
endocytosis by caveolae under the control of Abl family tyrosine
kinases. Increasing number of studies pointed out the efficacy of
inhibiting Abl family tyrosine kinases for regulating permeability
of BECs in inflammatory conditions; which was, however,
unknown for IgG kinetics and even for homeostatic conditions.
In contrast to the previous considerations22,23, major Fcγ
receptors seem to be dispensable for the IgG extravasation pro-
cess. Although FcRn was mandatory for the transportation of IgG
through the placenta (Fig. 4d) as we previously demonstrated39,
FcRn was dispensable for transportation of IgG through the blood
vessels to the skin interstitium. Consistently, we showed that
extravasation of human pemphigus autoantibodies (which
belongs to either IgG1 or IgG4) to the skin was blocked by
imatinib. It may also be possible that other subtypes of Igs share
this transport mechanism, which requires further investigation.
Our results also imply that there may be a distinct endocytic
pathway for IgG, as opposed to dextran, that is generally con-
sidered as a marker of fluid-phase endocytosis49. Although it is
considered that IgG is also taken up by fluid-phase endocytosis by
BECs22, there might be unknown factors or rules that govern the
choice of endocytic vesicle as a cargo bed in BECs under various
settings.
In our study, it is possible that Abl family tyrosine kinases or
the depletion of Fcγ receptors might have also affected the
function of immune cells in vivo. However, since the dissociation
of cell–cell adhesion between keratinocytes can be induced solely
by deposition of anti-Dsg3 Ab to keratinocytes without con-
tribution of immune cells31, we think that in our passive murine
pemphigus model, we could evaluate the direct effect of Abl
family tyrosine kinases on IgG kinetics. This insight into the basic
IgG kinetics in vivo, as well as the efficacy of Abl family tyrosine
kinases on IgG kinetics, may attract interest from both
the immunological and the clinical fields. At the same time, with
the increasing attention to Abl family tyrosine kinases as a tool
for treating not only cancerous but also noncancerous
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diseases26,28,42,46–48, we should also note that these reagents can
be of aid in the dysregulation of host immunity by reducing IgG
concentration in the peripheral tissues.
The extravasation of IgG should be beneficial for the host
defense against infectious pathogens in peripheral tissues, and
yet can also trigger autoantibody-mediated manifestations, as
such demonstrated in our murine pemphigus model. Our
observations were consistent with previous in vitro reports that
indicate the importance of c-Abl on caveolae-mediated endo-
cytosis29,30. We propose that the strategy to block Abl family
tyrosine kinases, such as by imatinib or AICAR, might be a
useful alternative in the treatment of autoantibody-mediated
disorders. Although it is important to note that the efficacy of
these drugs might vary among target tissues due to the differ-
ences in the rigidity of the intercellular barrier of blood capil-
laries, as well as the dependency on the transcellular pathway
for IgG extravasation7. Autoantibody-mediated encephalitis or
retinopathy can be other targets, considering the tight blood
barrier structures in these tissues. On the other hand, con-
sidering the efficacy of imatinib on IgG extravasation upon
inflammation (Fig. 5a), together with its effect on pathological
vascular hyperpermeability24–26, imatinib might also be useful
even with disruption of the blood vessel barrier. We did not
precisely exclude the effect of imatinib on the paracellular IgG
diffusion in the skin under both homeostatic and inflammatory
condition in this study, which would be another important
issue to address in the future. Besides, we found that imatinib
had little effect on the transition of serum anti-Dsg3 Ab titers.
Although the definite mechanism is still undiscovered, it seems
to be consistent with the notion that BECs not only recycle but
also degrade the internalized IgG23,53. We assume that both the
degradation and recycling processes were inhibited by blocking
the endocytosis of IgG, resulting in equivalent serum auto-
antibody titers.
Conversely, our study has several limitations and issues to be
solved. First, it remains unsolved how Abl family tyrosine kinases
are activated under homeostatic conditions, although previous
reports implied that physiological oxidative stresses to BECs
might be involved in this process29,30. Second, the contribution of
other molecules such as c-Src kinase in regulating IgG extra-
vasation needs to be clarified. Although it is considered that
imatinib has low affinity to c-Src kinase54, c-Src kinase is also
known to govern caveolar function;55 therefore, intervention of
other unknown molecules might be undeniable. As mentioned,
our most important query is whether Abl family tyrosine kinases
can be applied to treat autoantibody-mediated disorders. On this,
we are now undergoing a clinical trial of imatinib in patients with
autoimmune-blistering diseases in Kyoto University Hospital
(The study is registered with the UMIN Clinical Trials Registry,
number UMIN000030865).
In conclusion, our study provided insights into the kinetics of
IgG extravasation in vivo and revealed a previously unknown
immunomodulatory aspect of inhibitors for Abl family tyrosine







































































































Fig. 6 Abl family tyrosine kinase inhibitors reduce IgG transport through BECs. a The left panels show hIgG distribution in BECs treated with siRNA that
targets caveolin 1 (CAV1), c-ABL (ABL1), or nontargeting siRNA. Scale bar= 20 μm. The right panel shows ΔA594-MFI of BECs of each cell (n= 30, 22, and
20 cells, respectively), and BECs treated with siRNA that targets caveolin 1(CAV1), c-ABL (ABL1), or nontargeting siRNA (E, n= 22, 23, and 25 cells,
respectively) after the IgG endocytosis assay. *P < 0.05 (a one-way ANOVA test). b–d IgG transition through HDMECs was evaluated by the in vitro
transwell permeability assay under thrombin stimulation, treated either with imatinib at 0.1–10 μM (b), asciminib at 0.1–10 μM (c), or GNF-2 at 0.1–20 μM
(d), or vehicle (n= 3 wells, each). *P < 0.05 (a one-way ANOVA test). e IgG1-MFI of ear epidermis 24 h after 100 μg of AK18 injection pretreated with
vehicle or AICAR (n= 6, respectively). *P < 0.05 (a one-way ANOVA test). The precise protocol is described in the “Methods” section. In each figure, the
error bars represent the standard deviation of a data set
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disorders. A better understanding of the IgG kinetics might serve
as an asset in the search for therapeutics of autoantibody-
mediated disorders, and also in host immunity.
Methods
Mice. Female 8- to 10-week-old C57BL/6-background mice were used in this study
unless otherwise indicated. The age of mice used in AK23 trials was between 9 and
10 weeks old. C57BL/6 and BALB/c mice were purchased from SLC (Shizuoka,
Japan).
FcγRIIb-deficient mice36 and FcRg-deficient mice37 were gifted from Dr T.
Takai, and both mouse strains were backcrossed with C57BL/6 mice for at least
more than ten generations before the experiments. β2m-deficient mice were gifted
from Dr Y. Hamasaki56.
Mas-TRECK mice were as described previously57, and to deplete mast cells
in vivo, 250 ng of diphtheria toxin dissolved in 200 μl of PBS was intraperitoneally
injected to Mas-TRECK mice for 5 consecutive days. The experiments were
conducted the next day following the last injection of diphtheria toxin.
VE-cadherin-CreERT2 transgenic mice33 were mated with dynamin 1 and 2
double conditional knockout mice32 to establish VE-cadherin-CreERT2; D1D2-
floxed mice. Both strains were kindly gifted from Dr Y. Kubota, and mice were
backcrossed with C57BL/6 mice for at least more than ten generations before the
mating. Two milligrams of tamoxifen (Sigma Aldrich, St. Louis, MO) was dissolved
in 200 μl of ethanol/sunflower oil (1:8) and intraperitoneally injected to mice for 5
consecutive days. The experiments were conducted 6–7 days after the last injection
of tamoxifen. Cre negative littermates were used as controls.
Passive murine pemphigus model. Hybridoma cells that produce pathogenic
(AK23) and nonpathogenic (AK18) anti-mouse Dsg3 monoclonal antibodies were
provided from Keio Unversity31. To obtain antibodies, these cells were cultured in
GIT medium (Wako, Tokyo, Japan) at 37 °C for 14 days and IgG was purified from
culture supernatant using a Protein G HiTrap column (GE Healthcare, Uppsala,
Sweden). For flow cytometric analysis, 100 μg (to check IgG1-MFI in untreated
ears) or 20 μg (to check IgG1-MFI in inflamed ears) of AK18 was intravenously
administered to mice via the tail vein, and the ear skin was collected 24 h later
unless otherwise indicated. For immunohistochemical analysis, 100 μg of AK23 was
intravenously administered via the tail vein, and the ear skin was collected 1–5 days
later. Otherwise, 50 or 5 μg of AK23 was intradermally administered to the back
skin or the ear skin of mice, respectively. Hair loss started 4–5 days after AK23
injection, and progressed until 10 days after AK23 injection. The images of hair loss
were obtained 10 days after AK23 injection. The serum levels of anti-mouse Dsg3
Ab were analyzed using an enzyme-linked immunosorbent assay (ELISA) kit
(MBL, Nagoya, Japan) according to the manufacturer’s instructions.
Cell isolation and flow cytometry. To obtain a single-cell suspension from the
epidermis, the dorsal halves of mouse ears were floated on 5 mgml−1 dispase II
(Godo Shusei Co., LTD, Tokyo, Japan) dissolved in RPMI 1640 (Invitrogen,
Carlsbad, CA) containing 10% fetal calf serum (FCS) for 30 min at 37 °C. Subse-
quently, the epidermis was manually separated from the dermis by fine tweezers.
The epidermis was then floated on 0.25% trypsin-EDTA for 8 min at 37 °C and
filtered through a 70-μm nylon mesh. For the dermal cell suspension, the dermis
was digested with 0.33 mgml−1 liberase TL (Roche, Basel, Switzerland) dissolved in
RPMI 1640 containing 10% FCS for 60 min at 37 °C and filtered through a 70-μm






































































Fig. 7 Imatinib prevents the development of murine pemphigus manifestations. a The upper panel shows manifestation of hair loss 10 days after
intravenous injection of AK23, pretreated with imatinib or vehicle. The percentage of mice that developed severe hair loss (over 30% of their back skin
area) was plotted in the lower panel (n= 10 or 13, respectively, in accumulation of three trials). *P < 0.05 (a log-rank test). b Histology of hair follicles in the
back skin of mice 4 days after intravenous injection of AK23 pretreated with imatinib or vehicle. Arrowheads represent the disruption of cell–cell adhesion
in follicular keratinocytes. Scale bar= 50 μm. c Immunohistochemical evaluation for AK23 deposition (green) in interfollicular and follicular keratinocytes
in the ear skin of mice 1, 2, or 5 days after intravenous injection of AK23, pretreated with imatinib or vehicle. d Serum AK23 levels 24 h after intravenous Ab
injection, pretreated with imatinib or vehicle (n= 4 for day 0–3, n= 3 for day 5). e The manifestation of hair loss after intradermal AK23 injection into the
back skin of mice pretreated with imatinib or vehicle. f Immunohistochemical evaluation for AK23 deposition (green) in interfollicular and follicular
keratinocytes in the ear skin of mice after intradermal AK23 injection into the ears, pretreated with imatinib or vehicle. In c and f, yellow arrows indicate
intercellular AK23 deposition. Blue represents nuclei stained by DAPI. White dotted line represents the border between the epidermis or the hair bulb and
the dermis. Scale bar= 50 μm. In each figure, the error bars represent the standard deviation of a data set
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added to dispase II and liberase TL solution in order to evaluate the amount of
intercellular AK18 in BECs.
To stain cells, anti-mouse CD45 (Cat. 560501, clone 30-F11), E-cadherin (Cat.
560061, clone 36/E-Cadherin), IgG1 (Cat. 550874, clone X56), CD11b (Cat.
560455, clone M1/70), Ter119 (Cat. 560512, clone TER-119), and MHC classII
(Cat. 563163, clone M5/114) Abs were purchased from BD Bioscience (San Jose,
CA). Anti-mouse CD31 (Cat. 102516, clone MEC13.3), gp38 (Cat. 127407, clone
8.1.1), F4/80 (Cat. 123114, clone BM8), FcγRI (Cat. 139303, clone X54-5/7.1),
FcγRII/III (Cat. 101307, clone 93), FcγRIV (Cat.149503, clone 9E9), Pdgfr-α (Cat.
135905, clone APA5), and CD200R3 (Cat. 142206, clone Ba1.3) Abs were
purchased from BioLegend (San Diego, CA). Anti-mouse c-Kit (Cat. 17-1171-83,
clone 288), FcεRI (Cat. 11-5898-85, clone MAR-1), and Pdgfr-β (Cat. 12-1402-81,
clone APB5) Abs were purchased from eBioscience (San Diego, CA). Anti-mouse
FcRn Ab (Cat. AF6775) was purchased from R&D systems (Minneapolis, MN),
and stained subsequently with anti-goat A647 secondary Ab (Invitrogen). Fixable
viability dye (Cat. 65-0865-18, eBioscience) was used to exclude dead cells.
To check IgG1-MFI in the epidermis, epidermal cells were stained with
antibodies against CD45, E-cadherin, and IgG1, then fixed with Cytofix/Cytoperm
(Cat. 51–2090KZ, BD Bioscience), and underwent flow cytometric analysis. We
gated CD45−E-cadherin+ fraction to exclude intraepidermal immune cells and
cell-debris. To evaluate cell-internalized IgG1 in dermal BECs, dermal cells were
stained with fixable viability dye, antibodies against CD31, gp38, Ter119, and
CD45. Cells were then fixed and permeabilized with Cytofix/Cytoperm and Perm
wash (Cat. 51-2091KZ, BD Bioscience), and underwent intracellular staining with
anti-mouse IgG1 antibody for flow cytometric analysis.
To detect the extravasation of nonspecific IgG or dextran in the murine ears by
flow cytometry, 100–200 μg of fluorescein (A647)-conjugated mouse IgG (Cat. 015-
600-003, Jackson ImmunoResearch, West Grove, PA) and/or 1 mg of FITC-
conjugated 150 kDa dextran (Sigma Aldrich) was intravenously injected via tail
vein to mice or was intradermally injected to the ears of mice. The dermal cell
suspension was collected after extraction of epidermis with dispase II, and
subsequently digested with liberase TL, as mentioned above. Cells were stained
with fixable viability dye, anti-mouse CD45, CD11c, CD11b, MHC classII, and F4/
80. Cells were then fixed with Cytofix/Cytoperm for flow cytometric analysis.
Flow cytometric analysis was performed using LSR Fortessa (BD Bioscience)
and analyzed by FlowJo software (Tree Star, Ashland, OR). The exact sequential
gating strategy of dermal BECs is located in Fig. 2b. The gating strategies to check
Ab deposition to epidermis and dermal macrophages are located as Supplementary
Fig. 7A and 7B. Also, gating strategies of mast cells are located as Supplementary
Fig. 7C.
Time-lapse imaging of blood-circulating IgG by two-photon microscopy.
Female 8-week-old BALB/c mice were used for intravital-imaging analysis to avoid
the influence of melanin. Mice were positioned on the heating-plate on the stage of
a two-photon microscope, IX-81 (Olympus, Tokyo, Japan), and their ear lobes were
fixed beneath cover slips with a single drop of immersion oil. Subsequently, 5 mg of
human polyclonal IgG (Nihon Pharmaceutical Co. LTD, Tokyo, Japan) labeled
with FITC (Sigma Aldrich) was injected via the tail vein. Stacks of 15 images,
spaced 3.5 μm apart, were acquired every minute for 1 h. To evaluate in vivo IgG
kinetics, the single color-scale images of fluorescein were obtained and converted to
rainbow color-scale images according to fluorescent intensity using ImageJ soft-
whare58. Then, the blood vessel area and the interstitial space were manually
circumscribed9, and the MFI of each area at each time point was calculated using
ImageJ software. To induce skin inflammation, 20 μl of PMA (0.1 mgml−1 in
acetone; Sigma Aldrich) was painted on the ear 24 h before the IgG injection.
Immunohistochemistry of the murine ear skin. To detect AK23-induced hair
acantholysis, a disruption of cell–cell adhesion between follicular keratinocytes, the
murine dorsal skin samples were obtained 4 days after intravenous injection of
AK23, fixed in 10% formaldehyde, and embedded in paraffin. Samples were then
sliced at 5 μm, deparaffinized, and underwent hematoxylin and eosin staining.
To detect epidermal AK18 or AK23 deposition in the ear skin, the ear skin
samples were obtained 24 h after intravenous injection of antibodies, fixed in 4%
paraformaldehyde (PFA), and embedded in O.C.T. compound (Sakura Finetek,
Torrance, CA). Five micrometers of slices were treated with Image-iT FX signal
enhancer (Invitrogen), and incubated for 30 min at room temperature with goat
anti-mouse IgG A594 secondary Ab (Invitrogen). PBS or control mouse IgG1 (Cat.
400166, clone MOPC-21, BioLegend) was injected as negative controls. The slices
were mounted with ProLong Diamond Antifade Mountant with DAPI (Life
Technologies, Carlsbad, CA).
To detect epidermal autoantibody deposition after injecting sera from
pemphigus patients, sera from two pemphigus vulgaris patients (PV#1 and PV#2),
who were positive for anti-Dsg3 Ab but not anti-Dsg1 Ab, were collected for the
analysis. Among the IgG1-IgG4 subclasses, both sera were positive for the IgG1
and IgG4 subclasses. The ears of mice were collected 24 h after intravenous
injection of each serum, then fixed, mounted, and stained with anti-human IgG
FITC (Abcam, Cambridge, UK). With intravenous injection of each serum of PV#1
and PV#2 to adult mice via the tail vein, we determined that at least 100 μl of each
patient’s serum was required to obtain apparently positive results in the untreated
ears. Due to the limitation of the serum amount, the experiments using patients’
sera were performed in a single mouse and its control, twice, with similar results for
each serum.
To detect the extravasation of nonspecific IgG or dextran in the murine ears by
immunohistochemistry, 100–200 μg of fluorescein (A555 or A594)-conjugated
mouse IgG (Cat. 015-160-003 or 015-600-003, Jackson ImmunoResearch, West
Grove, PA) and/or 1 mg of FITC-conjugated 150 kDa dextran (Sigma Aldrich) was
intravenously injected via the tail vein to mice. Otherwise, 20 μg of fluorescein-
conjugated mouse IgG was intradermally injected to the ears. The ears of mice were
collected 24 h after injection and the dorsal halves of the ears were floated on 4%
PFA at 4 °C for a day. The ears were mounted with ProLong Diamond Antifade
Mountant without DAPI (Life Technologies, Carlsbad, CA).
These samples were observed under a fluorescent microscope, BZ-900
(KEYENCE, Osaka, Japan) or a confocal microscope (Nikon, Tokyo, Japan).
Reagents and in vivo blocking assay. To block caveolae-mediated endocytosis,
mice were intraperitoneally treated with 8 mg kg−1 body weight of nystatin (Sigma
Aldrich) 1 h before AK18 administration. Ear samples were evaluated for IgG1-
MFI 6 h after AK18 administration. Nystatin was first dissolved in dimethyl sulf-
oxide (DMSO) at 25 mgml−1, and diluted to the final concentration of 1 mgml−1
in distilled water (dH2O). DMSO dissolved in dH2O was used as the vehicle.
To block c-Abl, mice were intraperitoneally treated with imatinib mesylate
(5–150 mg kg−1 body weight day−1 dissolved in dH2O) (Wako) twice a day for 2
consecutive days before the administration of AK18, AK23, fluorescence-
conjugated mouse IgG, or fluorescence-conjugated dextran. For the evaluation of
hair loss, the development of hair loss in the back skin was evaluated for 10 days
post AK23 administration, pretreated with imatinib or dH2O (n= 10 or 13,
respectively). Alternatively, AICAR (Toronto Research Chemicals, Toronto,
Canada) was dissolved in dH2O and subcutaneously administrated 1 day at
0.5–0.75 mg kg−1 body weight day−1 before AK18 administration.
To block Pdgfr-α in vivo, mice were intravenously treated with 1 mg of APA5
(Cat. 562171, clone APA5, BD Bioscience) or 1 mg of control rat IgG 24 h before
the administration of AK18.
To block FcRn function, IVIG at 1.0 g kg−1 day−1 (human IgG obtained from
Nihon Pharmaceutical Co. Ltd, Tokyo, Japan) was injected intravenously via the
tail vein for 3 consecutive days to adult mice or pregnant mice (from E15.5 to
E17.5). AK18 was administered at 100 μg together with the final IVIG
administration. For the analyses, the ears of adult mice were collected the following
day. The fetuses were delivered at E18.5 by cesarean section, and the dorsal skin
was extracted for cell isolation and flow cytometry.
Cell culture and in vitro IgG endocytosis assay. HDBECs were purchased from
PromoCell (Heidelberg, Germany) and cultured in endothelial cell growth medium
MV (PromoCell) at 37 °C in 5% CO2 until reaching 70–80% confluency. For the
IgG endocytosis assay, cells were incubated in the presence of A594-conjugated
human IgG (Cat. 009-580-003, 10 μg ml−1; Jackson ImmunoResearch) for 1 h. To
block dynamin function, cells were treated with dynasore (100 μg ml−1; Santa Cruz
Biotechnology, Dallas, TX) for 30 min. To block caveolae-mediated endocytosis,
cells were cultured with nystatin (50 μg ml−1; Sigma Aldrich) for 30 min. To
evaluate the quantity of engulfed IgG in each cell, the cytoplasmic area of cells in a
high-power field (×40) was manually circumscribed using ImageJ58, and the MFI of
the signals from A594-IgG was measured. ΔA594-IgG was calculated by sub-
tracting the background MFI.
Immunocytochemistry of HDBECs. For immunocytochemistry, HDBECs were
incubated with A594-conjugated human IgG (Cat. 009-580-003, 10 μg ml−1;
Jackson ImmunoResearch, West Grove, PA) for 1 h, fixed with 4% PFA for 1 h at
4 °C, permeabilized with 0.1% triton-X100 in 1% bovine serum albumin/PBS, and
blocked with Image-iT FX signal enhancer (Invitrogen) before the staining. Sub-
sequently, cells were incubated with anti-EEA-1 Ab (Cat.2411, Cell Signaling
Technology, Danvers, MA) at room temperature for 1 h, washed and incubated
with anti-rabbit IgG A488 dye (Invitrogen) for 30 min at room temperature, and
mounted with ProLong Diamond Antifade Mountant with DAPI (Life Technol-
ogies). Alternatively, cells were incubated with HCS CellMask™ Green Stain (Cat.
H32714, Invitrogen) at 2 μg ml−1 for 30 min at room temperature, and mounted.
Otherwise, cells were stained with anti-caveolin 1 Ab (Cat. ab2910, Abcam) or anti-
clathrin Ab (Cat. ab21679, Abcam) overnight at 4 °C, incubated with anti-rabbit
IgG A488 dye (Invitrogen) for 30 min at room temperature on the following day,
and mounted. For the acid wash34, cells were washed with 0.2 M acetic acid in 150
mM NaCl at 4 °C after the IgG endocytosis assay and before the fixation. These
slides were observed under a fluorescent microscope, BZ-900 (KEYENCE).
Transwell permeability assay. HDMECs (PromoCell) were purchased and cul-
tured in endothelial cell growth medium MV (PromoCell) at 37 °C in 5% CO2 until
reaching 70–80% confluency. HDMECs were collected with the DetachKit (Pro-
mocell) and plated on the insert plates of Millicell-96 transwell (Merck Millipore,
Darmstadt, Germany) at 5 × 104 cells in 75 μl medium/well. Two hundred and
fifty microliters of medium was added to the receiver plate and incubated for 2 days
at 37 °C in 5% CO2. The insert plates were then replaced to the new receiver plate.
The medium was aspirated from the insert plates, and new medium with imatinib,
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asciminib, or GNF-2 was added at 50 μl/well at various concentrations as indicated
in each figure, and incubated for 3 h. Asciminib and GNF-2 were synthesized in
Mitsubishi Tanabe Pharma Corporation. Subsequently, 10 μl of FITC-conjugated
human IgG at 187.5 μgml−1 (Jackson ImmunoResearch) was added to the insert
plates, and incubated for 30min. Ten microliters of thrombin was added at 5 Uml−1
and incubated for another 60min. Finally, the insert plates were removed, and
fluorescence intensity of the FITC-conjugated human IgG in the receiver plates was
measured by EnVision (PerkinElmer, Waltham, MA).
In vitro siRNA assay. The following control siRNA and siRNA that targets
caveolin 1 (CAV1), clathrin heavy chain (CLTC), or c-ABL (ABL1) were pur-
chased from GE healthcare (Pollards Wood, UK): Accell human CAV1 siRNA-
SMART pool (Cat. E-003467-00-0005), Accell human CLTC siRNA-SMART
pool (Cat. E-004001-00-0005), Accell human ABL1 siRNA-SMART pool (Cat. E-
003100-00-0005), and Accell Nontargeting Pool (Cat. D-001910-10-05).
HDBECs (PromoCell) were treated with each siRNA following the manu-
facturer’s protocol.
Briefly, HDBECs were cultured in endothelial cell growth medium MV
(PromoCell) with 5% serum concentration, at 37 °C in 5% CO2, until reaching
40–50% confluency. The medium was then exchanged to siRNA containing MV
medium with 2.5% serum concentration, and cultured for another 3 days at 37 °C
in 5% CO2. Down regulation of each mRNA expression was verified at this time
point by reverse transcription polymerase chain reaction. Subsequently, the
medium was again exchanged to MV medium with 5% serum concentration, and
cells were cultured for additional 3 days at 37 °C in 5% CO2. After that,
immunohistochemistry to check the down regulation of protein expression of
caveolin 1 and clathrin, and the IgG endocytosis assay were performed as
mentioned.
Quantitative PCR analysis. Total RNA was isolated from the cells lysed in buffer
RLT by the RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA was synthesized
with a PrimeScript RT reagent kit and random hexamers according to the man-
ufacturer’s protocol (TaKaRa, Shiga, Japan). A LightCycler 480 and LightCycler
SYBR Green I Master mix were used according to the manufacturer’s protocol
(Roche) for quantitative PCR (primer sequences are as follows: CAV1; Forward,
CTGTCGGAGCGGGACATC/Reverse, TGTTTAGGGTCGCGGTTGAC. CLTC;
Forward, GCACTGAAAGCTGGGAAAACT/Reverse, TCCGTAACAAGAGCA
ACCGT. ABL1; Forward, GCTGTTATCTGGAAGAAGCCCT/Reverse, GCAACG
AAAAGGTTGGGGTC). The expression of each gene was normalized to that of
the internal control gene, GAPDH (Forward, CATGAGAAGTATGACAACAG
CCT/Reverse, AGTCCTTCCACGATACCAAAGT).
Electron microscopy. Mice were anesthetized, and perfused with PBS containing
heparin and then with half Karnovsky solution, containing 2% PFA and 2% glu-
taraldehyde (Wako) in 0.1 M cacodylic acid (Wako). Subsequently, the ears were
cut into 1 × 3 mm pieces, prefixed with half Karnovsky solution overnight at 4 °C,
and fixed in 1% osmium before the dehydration and epon embedding. Samples
were then ultrathin-sliced and underwent uranium and lead staining, and observed
using transmission electron microscope (H-7650, Hitachi High-Technologies
Corporation, Tokyo, Japan).
Statistics. Unless otherwise indicated, data are presented as means ± SDs and each
data point is representative of three independent experiments. As described in the
“Methods” section, due to the limitation of the serum amount, the experiments
using patients’ sera were performed in a single mouse and its control, twice, with
the similar results for each serum. Statistical analyses were performed using a
GraphPad prism (GraphPad Software, Inc., CA). Normal distribution was assumed
for all samples. Unless indicated otherwise, a parametric Student’s t-test or a one-
way ANOVA test was used for comparing groups and log-rank test was used for
survival curves. A value of P < 0.05 at 95% confidence intervals was considered to
indicate statistical significance. NS indicates not significant.
Study approval. All animal experimental procedures were ethically approved by
the institutional Animal Care and Use Committee in Kyoto University Faculty of
Medicine (182309). In all experiments, we complied with all relevant ethical reg-
ulations for animal testing and research. All experiments using human samples in
this study was approved by the Medical Ethics Committee of the Kyoto University
Graduate School of Medicine, and conducted according to the Declaration of
Helsinki principles. Informed consent was obtained before the sampling of serum
from each patient.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1b, g, 2c, e–h, 3b–f, 4b–i, 5a–f, 5h, 6a–e, 7a, d, and
Supplementary Figs. 3A, 4B, 4E, and 5B are provided as a Source Data file.
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